Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease.
Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease.
复制标题
足细胞中 CLDN5 的缺失会导致 WIF1 失调,从而激活 WNT 信号传导并导致肾脏疾病
DOI:
10.1038/s41467-022-29277-6
复制
发表时间:
2022-03-24
影响因子:
16.6
通讯作者:
Gong Y
中科院分区:
文献类型:
--
作者:
Sun H;Li H;Yan J;Wang X;Xu M;Wang M;Fan B;Liu J;Lin N;Wang X;Li L;Zhao S;Gong Y
Although mature podocytes lack tight junctions, tight junction integral membrane protein claudin-5 (CLDN5) is predominantly expressed on plasma membranes of podocytes under normal conditions. Using podocyte-specific Cldn5 knockout mice, we identify CLDN5 as a crucial regulator of podocyte function and reveal that Cldn5 deletion exacerbates podocyte injury and proteinuria in a diabetic nephropathy mouse model. Mechanistically, CLDN5 deletion reduces ZO1 expression and induces nuclear translocation of ZONAB, followed by transcriptional downregulation of WNT inhibitory factor-1 (WIF1) expression, which leads to activation of WNT signaling pathway. Podocyte-derived WIF1 also plays paracrine roles in tubular epithelial cells, as evidenced by the finding that animals with podocyte-specific deletion of Cldn5 or Wif1 have worse kidney fibrosis after unilateral ureteral obstruction than littermate controls. Systemic delivery of WIF1 suppresses the progression of diabetic nephropathy and ureteral obstruction-induced renal fibrosis. These findings establish a function for podocyte CLDN5 in restricting WNT signaling in kidney. Claudin-5 is a tight junction integral membrane protein, but it is also expressed in mature podocytes which lack tight junctions. Here the authors report that podocyte claudin-5 regulates WNT signaling activity by modulating WIF1 expression, and its downregulation contributes to kidney disease progression in mice.
登录
查看更多内容
影响因子:
11.4
作者:
Balda, MS;Matter, K
通讯作者:
Matter, K
影响因子:
7.8
作者:
Nitta, T;Hata, M;Tsukita, S
通讯作者:
Tsukita, S
影响因子:
19.6
作者:
Done, S. C.;Takemoto, M.;Tryggvason, K.
通讯作者:
Tryggvason, K.
DOI:
10.1073/pnas.0504166102
发表时间:
2005-07-12
影响因子:
11.1
作者:
Lehtonen, S;Ryan, JJ;Farquhar, MG
通讯作者:
Farquhar, MG
DOI:
10.1038/mtm.2014.14
发表时间:
2014
期刊:
Molecular therapy. Methods & clinical development
影响因子:
--
作者:
通讯作者:
--